Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For all groups:
- People who are willing and able to take part in the research and provide body fluid or tissue samples
- People who are willing and able to give their formal consent to participate
For Group 001 (Acute Myeloid Leukaemia):
- People who have a confirmed diagnosis of Acute Myeloid Leukaemia (AML), as classified by the World Health Organization (WHO)
- People whose AML developed as a result of another condition or prior treatment (called secondary AML) are also eligible
For Group 002 (Follicular Lymphoma — all subgroups):
- People who have a confirmed diagnosis of Follicular Lymphoma (Subgroups A through D)
- People who are able to provide a baseline tissue or fluid sample that reflects their current disease, as described in the study laboratory manual
Group 002A (Newly diagnosed, on watch and wait):
- People who have been on active monitoring (watching without treatment) for around 6 months, or who are planned to be monitored this way
Group 002B (Newly diagnosed, high risk):
- People who are planned to start their first course of treatment for Follicular Lymphoma
- People whose disease meets at least one high-risk marker, such as a high score on the Follicular Lymphoma International Prognostic Index (FLIPI), a high tumour burden as measured by a specific European scoring system (GELF), or a blood protein level called LDH that is above the normal range
Group 002C (Relapsed or treatment-resistant):
- People whose Follicular Lymphoma came back or stopped responding within 24 months of completing their first course of treatment, and who have not yet started a second course of treatment
Group 002D (Transformed Follicular Lymphoma):
- People whose Follicular Lymphoma has been confirmed by tissue testing to have transformed into a more aggressive type of lymphoma
Who may not be able to join:
For all groups:
- People who are not willing or able to follow the study procedures
For Group 001 (AML):
- People who have already received any standard treatment for AML
For Group 002A:
- People who have already received treatment for Follicular Lymphoma
- People whose disease is classified as high risk based on any of the following: a high FLIPI score, a high tumour burden by GELF criteria, or an LDH blood level above the normal range
- People whose tumour has been surgically removed and who currently show no evidence of disease (confirm with trial site)
For Group 002B:
- People who are planned for active monitoring rather than treatment
- People who have already received treatment for Follicular Lymphoma
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Thompson, MD, PhD, FASCO, Tempus AI
Phone: 800-739-4137
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess biomarker landscape in the progression as well as baseline biospecimen samples and correlate with with real-world outcomes across multiple hematologic indications.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.